Serum legumain is a potential biomarker for community-acquired pneumonia: a prospective cohort study

血清半胱氨酸蛋白酶是社区获得性肺炎的潜在生物标志物:一项前瞻性队列研究

阅读:1

Abstract

Background: Legumain is a cysteine endopeptidase that belongs to the C13 family. Many studies have revealed that legumain plays a vital pathogenic role in various respiratory diseases. The aim of this study was to explore the role of legumain in community-acquired pneumonia (CAP). Methods: Serum samples were collected from 293 CAP patients on admission. The concentration of serum legumain was detected via an enzyme-linked immunosorbent assay. The relationship between serum legumain and CAP was assessed. Results: Serum legumain concentrations were increased in severe CAP patients compared to the concentrations of mild CAP patients. The Spearman rank correlation coefficient suggested that the serum legumain concentration was strongly associated with many clinical indicators. Additionally, linear regression analysis revealed that the serum legumain concentration was positively correlated with the CURB-65, PSI, SMART-COP, and APACHE II scores. Moreover, the serum legumain concentration on admission was elevated in CAP patients who underwent mechanical ventilation, vasoactive agent therapy, ICU admission, and who died during hospitalization. CAP patients with higher serum legumain expression had poor prognostic outcomes. The predictive value of the serum legumain concentration for prognosis was similar to that of the severity score. Conclusions: Serum legumain concentration is positively related to disease severity and a poor prognosis, indicating that serum legumain can be used as an indicator of disease severity and a prognostic indicator for CAP patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。